EDA Stock Chart & Stats
€5.20
€0.15(2.97%)
At close: 4:00 PM EDT
€5.20
€0.15(2.97%)
Day’s Range― - ―
52-Week Range€1.01 - €5.35
Previous CloseN/A
Volume220.00
Average Volume (3M)0.00
Market Cap
€198.91M
Enterprise Value€152.21
Total Cash (Recent Filing)€15.01M
Total Debt (Recent Filing)€27.79M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 13, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding37,481,987
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.35
Price to Sales (P/S)1.74
P/FCF Ratio-5.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.12Price Target Upside94.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.75
Revenue Forecast (FY)€54.86M
Bulls Say, Bears Say
Bulls Say
Rising Procedure VolumesSharply higher U.S. procedure volumes indicate accelerating physician adoption and greater utilization of installed systems. This durable utilization growth supports recurring consumable and service revenue, improves unit economics over time, and compounds installed‑base value for sustained top‑line expansion.
Rapid HIFU Revenue GrowthA 78% YoY jump in HIFU revenue and repeated capital system sales show the business is scaling placements. More systems create a reliable base for recurring disposables and services, support operating leverage as revenues rise, and underpin a multiyear growth runway if adoption persists.
Strong Clinical Evidence & Indication ExpansionRobust HIFI‑2 outcomes materially strengthen clinical credibility, lowering barriers to reimbursement and guideline alignment. Durable clinical validation supports broader indication expansion (e.g., endometriosis, BPH), increases physician confidence, and helps entrench the technology in standard care pathways.
Bears Say
Negative Cash FlowMaterial negative operating and free cash flows show the company is burning cash to fund growth and operations. Persistent cash deficits increase dependence on external financing, raise dilution or leverage risk, and could restrict spending on commercialization, training, and clinical programs critical for durable HIFU adoption.
Sustained Operating LossesOngoing operating losses and wider net deficits reflect limited operating leverage at current scale and rising SG&A. Continued unprofitability can erode equity, impede internal reinvestment, and force tradeoffs between growth and margin preservation unless scale or expense discipline materially improves.
Structural Financing / Dilution RiskShareholder approval for broad capital‑increase authority institutionalizes equity issuance as a financing option. While it provides liquidity flexibility, reliance on share issuance creates a persistent dilution risk and may alter capital allocation priorities, affecting long‑term per‑share returns for existing investors.
EDAP TMS News
EDA FAQ
What was EDAP TMS’s price range in the past 12 months?
EDAP TMS lowest stock price was €1.01 and its highest was €5.35 in the past 12 months.
What is EDAP TMS’s market cap?
EDAP TMS’s market cap is €198.91M.
When is EDAP TMS’s upcoming earnings report date?
EDAP TMS’s upcoming earnings report date is Aug 13, 2026 which is in 7 days.
How were EDAP TMS’s earnings last quarter?
EDAP TMS released its earnings results on May 07, 2026. The company reported -€0.208 earnings per share for the quarter, missing the consensus estimate of -€0.178 by -€0.03.
Is EDAP TMS overvalued?
According to Wall Street analysts EDAP TMS’s price is currently Undervalued.
Does EDAP TMS pay dividends?
EDAP TMS does not currently pay dividends.
What is EDAP TMS’s EPS estimate?
EDAP TMS’s EPS estimate is -0.19.
How many shares outstanding does EDAP TMS have?
EDAP TMS has 37,481,987 shares outstanding.
What happened to EDAP TMS’s price movement after its last earnings report?
EDAP TMS reported an EPS of -€0.208 in its last earnings report, missing expectations of -€0.178. Following the earnings report the stock price went up 3.448%.
Which hedge fund is a major shareholder of EDAP TMS?
Currently, no hedge funds are holding shares in DE:EDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EDAP TMS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€10.12 (94.60% Upside)
€10.12 (94.60% Upside)
Blogger Sentiment
Bullish
DE:EDA Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €36.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
152.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.03%
Trailing 12-Months
Company Description
EDAP TMS
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
EDA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial and clinical momentum centered on Focal One Robotic HIFU: record total and HIFU revenue, large YoY increases in procedures and capital sales, improved gross margins, meaningful clinical validation (HIFI-2) and international expansion across multiple indications. Offsetting these positives are near-term financial pressures from higher operating expenses, a wider operating and net loss, cash drawdown and inventory build as the company invests to support growth. The firm mitigated liquidity concerns with an approx. $14M EIB tranche and reiterated 2026 guidance, signaling confidence in continued HIFU growth.View all DE:EDA earnings summariesEDA Stock 12 Month Forecast
Average Price Target
€10.12
▲(94.60% Upside)